Pursuant to section 20 of the Medicines Act 1981 (“Act”), the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturers:
|
Arcoxia
Etoricoxib 30mg
Film coated tablet
Merck Sharp & Dohme (New Zealand) Limited
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturers:
|
Arcoxia
Etoricoxib 60mg
Film coated tablet
Merck Sharp & Dohme (New Zealand) Limited
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturers:
|
Arcoxia
Etoricoxib 90mg
Film coated tablet
Merck Sharp & Dohme (New Zealand) Limited
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturers:
|
Arcoxia
Etoricoxib 120mg
Film coated tablet
Merck Sharp & Dohme (New Zealand) Limited
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Perjeta
Pertuzumab 420mg equivalent to 30mg/mL
Concentrate for infusion
Roche Products (NZ) Limited
Roche Diagnostics GmbH, Mannheim, Germany
|
Dated this 24th day of February 2017.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
Gazette.govt.nz